Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569242 · ClinicalTrials.gov registry record · Phase 3
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
A Phase 3 study, sponsored by Ono Pharmaceutical Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 419
- Enrollment target
NCT02569242: Completed Phase 3 study, sponsored by Ono Pharmaceutical Co..
NCT02569242 is a Phase 3 study that has completed, run by Ono Pharmaceutical Co.. The registered enrollment target is 419 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02569242, a Phase 3 study, has completed, sponsored by Ono Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 419 participants
- Enrollment target
Study Summary
The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
Interventions
- DRUG Nivolumab
- DRUG Docetaxel/Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2020-10-23 |
| Phase | Phase 3 |
What the finished NCT02569242 record still lists
NCT02569242 is an interventional study that assigns participants to a tested intervention. The registered 419 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02569242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02569242 about?
NCT02569242 is a clinical study titled "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer". The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
What is the current status of trial NCT02569242?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2015-12-14. Estimated completion is 2020-10-23.
What interventions are being tested in trial NCT02569242?
The interventions under investigation include: Nivolumab (DRUG), Docetaxel/Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02569242?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02569242's enrollment target sits among peer trials
419 899th of 2000 higher than 1,101 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI